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Effect of telehealth on glycaemic control: analysis
of patients with type 2 diabetes in the Whole
Systems Demonstrator cluster randomised trial
Adam Steventon1*, Martin Bardsley1, Helen Doll2, Elizabeth Tuckey1 and Stanton P Newman3
Abstract
Background: The Whole Systems Demonstrator was a large, pragmatic, cluster randomised trial that compared
telehealth with usual care among 3,230 patients with long-term conditions in three areas of England. Telehealth
involved the regular transmission of physiological information such as blood glucose to health professionals
working remotely. We examined whether telehealth led to changes in glycosylated haemoglobin (HbA1c) among
the subset of patients with type 2 diabetes.
Methods: The general practice electronic medical record was used as the source of information on HbA1c. Effects
on HbA1c were assessed using a repeated measures model that included all HbA1c readings recorded during the
12-month trial period, and adjusted for differences in HbA1c readings recorded before recruitment. Secondary
analysis averaged multiple HbA1c readings recorded for each individual during the trial period.
Results: 513 of the 3,230 participants were identified as having type 2 diabetes and thus were included in the
study. Telehealth was associated with lower HbA1c than usual care during the trial period (difference 0.21% or
2.3 mmol/mol, 95% CI, 0.04% to 0.38%, p = 0.013). Among the 457 patients in the secondary analysis, mean HbA1c
showed little change for controls following recruitment, but fell for intervention patients from 8.38% to 8.15% (68 to
66 mmol/mol). A higher proportion of intervention patients than controls had HbA1c below the 7.5% (58 mmol/mol)
threshold that was targeted by general practices (30.4% vs. 38.0%). This difference, however, did not quite reach
statistical significance (adjusted odds ratio 1.63, 95% CI, 0.99 to 2.68, p = 0.053).
Conclusions: Telehealth modestly improved glycaemic control in patients with type 2 diabetes over 12 months.
The scale of the improvements is consistent with previous meta-analyses, but was relatively modest and seems
unlikely to produce significant patient benefit.
Trial registration number: International Standard Randomized Controlled Trial Number Register ISRCTN43002091.
Background
As the population ages, more people are living with
long-term conditions such as diabetes, putting pressure
on healthcare systems. Policy makers are exploring ways
to improve the efficiency of healthcare services, while in-
creasing or maintaining the quality of the care provided
[1]. Care of patients with diabetes typically aims to reduce
the risk of complications while minimizing harms associ-
ated with therapy, and thus increase longevity and health-
related quality of life. Glycaemic control as measured by
glycosylated haemoglobin (HbA1c) is a major goal [2], but
it remains difficult for many patients to achieve targeted
levels [3].
Self monitoring of blood glucose is well-established as
an important component of diabetes management for
insulin-treated patients [4] and has also been found to
be important in some studies of non-insulin dependent
patients [5,6]. Recently, increasing attention has been
paid to remote monitoring using telehealth devices,
which enable physiological information, including blood
glucose, to be sent on regular basis to healthcare profes-
sionals working remotely [7]. Telehealth might be more
effective at improving glycaemic control than ‘usual care’
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including standard self monitoring, as it involves goal
setting, transmission of blood glucose information, and
more immediate feedback from a healthcare professional
[8]. From a policy perspective, telehealth has been
attractive in part because the greater oversight and self
care believed to be associated with telehealth might lead
to fewer, expensive unplanned hospital admissions and
over time fewer long-term complications [9].
In a meta-analysis of 12 trials, telehealth was associ-
ated with lower HbA1c levels than usual care [10], but
the average sample size was small, at 216 patients. Over
half of the research participants represented in the meta-
analysis came from a single trial (the IDEATel trial), which
recruited 1,665 participants from medically underserved
areas of New York State. In this trial, the improvements in
HbA1c associated with telehealth were sustained over five
years, and amounted to 0.29% at the end of that period
(3.2 mmol/mol) [11-13]. IDEATel, however, began recruit-
ing participants in 2002 when telehealth was relatively
new. It used interventions designed by the evaluation team
and eligibility criteria that excluded some groups of
patients, such as those under age 55. It is therefore of
interest to know the effect of telehealth when it is pro-
vided to a broader set of patients as part of the routine
delivery of healthcare. People implementing telehealth
today will likely make different decisions to the IDEA-
Tel group, because they have access to commercially-
provided telehealth equipment and they operate in a
different context.
In order to address weaknesses in the evidence
about telehealth and other assistive technologies, the
Department of Health in England announced three large
demonstration sites in 2006 [14]. These sites were tasked
with implementing whole system redesign aimed at inte-
grating care teams, supported by a broad class of assistive
technologies. The resulting evaluation included a large
cluster randomised trial to assess the additional benefit
of telehealth within this context (the Whole Systems
Demonstrator trial, or WSD). Because pre-existing tele-
health trials tended to be small and heterogeneous [15],
the WSD aimed to have greater generalisability with
over 3000 patients. To accomplish this aim, a pragmatic
design was used [16] to compare telehealth with usual
care (described below). A parallel trial, conducted in the
same demonstration sites but not discussed in this
paper, assessed the impacts of telecare for people with
social care needs [17,18].
The WSD evaluation found some indications that tele-
health was associated with fewer unplanned (‘emergency’)
hospitalisations and deaths than usual care among a popu-
lation with diabetes, heart failure or chronic obstructive
pulmonary disease [19]. However, there were no overall
improvements in quality of life for patients [20], and no
evidence of cost effectiveness at usual willingness-to-pay
levels [21]. The effect of telehealth on clinical metrics such
as HbA1c has not previously been reported, but it would
help to clarify the potential mechanisms for the observed
effects and the role that telehealth can play towards meet-
ing important treatment goals.
While the current study tested whether telehealth led
to changes in glycaemic control among the subset of WSD
participants with type 2 diabetes, another strand of the
evaluation is assessing the effect of telehealth on disease-
specific quality of life for these patients. Existing qualita-
tive studies have assessed the patient, professional, and
organizational factors related to implementation [22-24].
Methods
Design of the Whole Systems Demonstrator trial
The WSD was designed as a pragmatic trial to assess the
impact of telehealth when introduced as part of the rou-
tine delivery of care. Unlike explanatory trials that com-
pare highly-specified interventions in controlled situations
on tightly defined cohorts of patients, pragmatic trials
often use broad eligibility criteria to enrol patients, test
flexible interventions as practiced by typical (not expert)
practitioners, and make comparisons with usual care [25].
Therefore, an important part of the evaluation design was
to leave aspects of the design of the telehealth interven-
tions to local teams. The protocol for the trial and evalu-
ation has already been published [14], along with a
detailed description of the interventions (Web Appendix
[21], and Web Appendix 2 [20]). We summarise the main
features below.
The Department of Health selected the WSD sites in
2006 through a competitive process because (a) they
were considered the most likely to succeed in scaling up
remote care as part of a whole system redesign, and (b)
they were considered representative of the range of local
health and social care systems in England [22]. Cornwall,
Kent and Newham in East London were chosen. In order
to recruit suitably large numbers of patients, and because
individual randomisation was unlikely to be acceptable to
stakeholders, cluster randomisation was used [14]. Thus,
all general practices in the three demonstration sites were
invited to participate by site teams, and the general prac-
tices that accepted the invitation were randomised accord-
ing to a centrally-administered minimisation algorithm to
provide patients for either telehealth or usual care.
Patient inclusion criteria specified only age 18 years or
over, plus a diagnosis of diabetes, chronic obstructive
pulmonary disease or heart failure. Patients with these
diagnoses were sourced from the existing lists of patients
registered at participating general practices, using rou-
tine primary and secondary care data and referral letters
from clinicians. Exclusion criteria related to the patient
not understanding the instructions for the equipment
(which were provided in English), or living in a home
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unsuitable for telehealth (for example, with inadequate
telephone line connection). Eligibility was not conferred
on the basis of a formal clinical assessment of disease
severity, and patients with additional co-morbidities (in
addition to the targeted long-term conditions) were not
excluded from participation.
Once potentially eligible patients had been identified,
they were written to at home and asked for their permis-
sion to share data with the research team so that their
eligibility could be confirmed. Thus, all participants signed
a consent form to agree to their details being examined to
establish their eligibility for the trial. Once eligibility had
been established, they were visited at home, where they
signed a further consent form to agree to participate in
the trial. Treatment allocations for patients followed those
of the general practices at which the patients were regis-
tered. Though patients were not told about these alloca-
tions until after consent had been given, the long period of
recruitment and cluster-randomised method meant it was
not always possible to blind those recruiting patients.
The target sample size for the trial was 3,000 patients,
based on the numbers needed to detect a 17.5% change
in the primary outcome (hospitalisation proportion) from
the levels assumed for usual care (with an intra-cluster
correlation of 0.001 and an assumed cluster size of 25)
[19]. Patient recruitment began in May 2008 and was
scheduled to end in September 2009, though a small
number of patients were recruited later.
The current study was conducted on the subset of
WSD patients who had diabetes as their ‘index condi-
tion’. In the WSD trial, these index conditions were
assigned in order to limit the number of disease-specific
questionnaires given to patients; where a patient had
more than one of the targeted long-term conditions, one
condition was selected using randomisation [20]. We
further restricted the sample to patients with type 2
(rather than type 1) diabetes by applying codes to the
diagnoses recorded in general practice data (codes given
in Additional file 1).
Interventions
The trial was not designed to investigate the effect of indi-
vidual service configurations or technologies [14]. Rather,
it sought to understand the effects of ‘telehealth’, as a class
of technologies that was added to standard support and
treatment, compared with standard care alone. Consistent
with the pragmatic design, sites were intentionally left to
design aspects of their own telehealth services, such that
there was some scope to tailor the services to local needs
and resources. However, in all sites, telehealth equipment
included a base unit (freestanding or a television set top
box) and a glucometer for diabetes, weighing scales for
heart failure and pulse oximeters for chronic obstructive
pulmonary disease. In addition, most intervention patients
received blood pressure monitors regardless of their long-
term condition. Patients with multiple conditions could
receive several peripherals. The peripherals communicated
with the base unit either wirelessly or by cable.
The telehealth equipment reminded participants to
take physiological measurements at the same time each
day for up to five days per week, with the frequency
adjusted according to participants’ individual clinical
histories. For example, participants with diabetes and
well-controlled blood glucose were typically asked to
take readings less frequently than participants whose
blood glucose was poorly controlled. In addition to the
telemonitoring aspect of the intervention, symptom
questions (e.g., ‘how are you feeling today compared
with yesterday?’) and educational messages were sent
to participants, either via the telehealth base unit or
via a set top box connected to a television, depending
on the study site.
Readings and answers to symptom questions were sent
to monitoring centres using store-and-forward technology
and secure servers. These centres were staffed with trained
support workers and either specialist nurses or commu-
nity matrons, depending on the site. Incoming biometric
readings were automatically transformed into a traffic light
classification of clinical risk, using thresholds (set initially
on the basis of clinical guidelines or by a clinician
responsible for the patient’s care) and algorithms that
differed between sites. Urgent readings (‘red flags’) were
reviewed and responded to daily, while other readings
could also be reviewed to identify deteriorations in
health. The scope of nurses to respond to the informa-
tion from patients varied according to their role, with
community matrons tending to have greater scope than
monitoring centre nurses to initiate clinical interven-
tions, such as a home visit or medicine titration within
certain limits. However, all nurses could evaluate the
patient, offer advice on disease management and refer
patients to other healthcare professionals, such as general
practitioners. Monitoring nurses were also able to transmit
health related questions, messages, or videos to educate
patients on their conditions, using the telehealth base unit
or set top box.
The Department of Health provided funding to the
demonstration sites for the telehealth interventions, as
well as project manager support for the implementation
of telehealth. Telehealth patients were not charged for
using the telehealth services (including calls to the mon-
itoring teams), but they were expected to have a tele-
phone line and electricity.
Control patients were not provided with any specific
support as part of their participation in the trial, though
a subset participated in nested questionnaire studies
[20,21]. They received usual care for the study sites,
which excluded telehealth but for some patients
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included self-monitoring of blood glucose as agreed with
their clinician. Control patients were offered telehealth
at the end of the 12-month trial period if they were still
eligible at that point.
Collection of data on HbA1c
The original trial protocol specified that HbA1c would be
collected at baseline, 3-month follow-up, and 12-month
follow-up. During the course of the trial, however, prac-
tical issues with the complex, community-based recruit-
ment procedure were identified that meant that the
protocol was revised so that bespoke clinical measures
were no longer collected. Instead, an analysis of the
electronic medical record was planned. In England,
these electronic records are used to calculate general
practice entitlements to performance-related pay under
the Quality Outcomes Framework (QOF). At the time
of the trial, QOF criteria included the maintenance of
codes for the diagnosis of diabetes, together with regu-
lar recording of HbA1c [26]. Although it was recognised
that these data would have limitations (discussed below),
it was expected that they would be more complete for
diabetes than for heart failure or chronic obstructive
pulmonary disease.
All general practices participating in the trial were
asked to share event-level data from the electronic
medical record for their registered adult patients [27].
Data were effectively anonymised (‘pseudonymised’)
before they were transferred to the evaluation team,
with patient identifiers removed and a unique patient
identifier (the ‘NHS number’) encrypted. The encrypted
NHS number was used to link the general practice data
to trial data sets [17].
The use of routine data meant that it was necessary to
exclude a small number of participants. First, we ex-
cluded patients who were not linked to the routine data
because NHS numbers were not available for encryption.
A second exclusion arose because our study focused on
the period from two years before a patient was recruited
in the trial to 12 months following that recruitment (or
death, if sooner) – this was known as the ‘observation
period’. We were concerned that, although all patients
were registered at a participating general practice at
the time of trial recruitment, they might have been reg-
istered at another general practice at some other point
during the observation period. If this other general
practice did not provide data for the evaluation (for ex-
ample, because it did not participate in the trial), then
we would have incomplete information about diagnosis
codes and HbA1c. As a result, we restricted the ana-
lysis to patients who were always registered with one of
the observed general practices during the observation
period.
Baseline characteristics
Baseline variables were derived using the general prac-
tice data (see codes in Additional file 1). Consistent with
other strands of the evaluation [19], for the purpose of
calculating variables, the trial start date was taken as the
date of telehealth installation for intervention patients,
and as the date of the initial project team visit for
controls.
In cluster-randomised trials, selection bias is theoret-
ically possible, either through systematic differences be-
tween practices in the control and intervention groups,
or through similar differences at the individual level
[28]. Following previous work [19], we present standar-
dised differences as a summary measure of differences
between groups at baseline; these were defined as the
differences in sample means (or proportions), divided
by the pooled standard deviation [29]. For continuous
variables, we also present the variance ratio, defined as
the variance in the intervention group divided by the
variance among controls [30].
Analysis of HbA1c frequency
We did not expect telehealth to alter the frequency with
which HbA1c was recorded in general practice (as indi-
cated by previous work [27]). To confirm this, we com-
pared numbers of HbA1c readings during the 12-month
trial period between treatment groups using chi-squared
tests. We also tested whether readings were made uni-
formly across the trial period, using the Kolmogorov-
Smirnov test and pooled data across both treatment
groups.
Comparison using repeated measures models
Analysis of HbA1c levels was conducted on an intention-
to-treat basis, using all HbA1c readings recorded within
the observation period. Analysis was conducted using a re-
peated measures linear regression model, which included
adjustment factors (fixed effects) for:
 Time (to account for secular trends in HbA1c);
 Trial arm (to account for differences in HbA1c
between treatment groups before the start of the
trial); and
 The interaction of trial arm and period (to estimate
the impact of allocation to the telehealth
intervention on HbA1c during the trial period).
As HbA1c readings for the same individual at different
time points will tend to be correlated, the model in-
cluded a first-order autoregressive correlation structure.
As patients at the same general practice will tend to
have more similar HbA1c readings than patients at
different general practices, the model included random
effects at the general practice (cluster) level. Finally, the
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model included random effects for the time of the read-
ings because these were not made on a fixed schedule.
Comparison of average HbA1c before and after
recruitment
In order to test the robustness of our results to the
models used, we conducted a series of secondary ana-
lyses. These were done on a ‘completer’ basis and thus
were restricted to the subset of study participants who
had at least one HbA1c recorded during the 12-month
trial period. Analyses were conducted at the patient
level, summarising the HbA1c readings recorded for
each individual during the trial period using the mean.
Differences between the treatment groups were then
assessed using mixed linear regression [31]. The model
included random effects for the general practice. As well
as doing unadjusted analysis, we also adjusted for a set
of baseline characteristics in the regression. These were:
last-recorded HbA1c prior to recruitment; age; sex; last-
recorded blood pressure, cholesterol quartile and BMI
quartile prior to recruitment; site (Cornwall, Kent or
Newham); smoking status; co-morbid ischemic heart dis-
ease; and diabetes management (insulin or non-insulin).
We conducted a range of sensitivity analyses with other
model specifications. These are described in Additional
file 2.
Proportions of patients below thresholds
At the time of this trial, general practices in England had
a specific goal to maintain glycosylated haemoglobin
(HbA1c) below 7.5% (58 mmol/mol) for patients with
diabetes. Therefore, we compared the proportion of
intervention and control patients under this threshold,
again averaging multiple readings for the same individual.
Between-group differences were assessed using mixed
logistic regression, with random effects for the general
practice. We also used graphical methods to compare
the distributions of HbA1c between intervention and
control groups (again, averaged over the trial period).
This was done using the HbA1c cut-off points adopted
in a previous study, which used electronic data from
general practices in the UK to examine the relationship
between HbA1c and survival [32].
Ethical approval
The Liverpool Research Ethics Committee (reference 08/
H1005/4) approved the study in all of the participating
sites.
Results
The full WSD trial involved 3,230 patients from 179
general practices [19]. Of these, 817 patients had dia-
betes as their index condition and were recruited before
30 September 2009 (n = 379 control; 438 intervention).
As previously stated, we excluded patients who were
not linked to the routine data (n = 37 control; 32 inter-
vention), did not have a continuous record of general
practice registration (n = 94 control; 76 intervention), or
did not have a confirmed diagnosis of type 2 diabetes
within the general practice data (n = 35 control; 30
intervention). This left us with 513 patients with type 2
diabetes (n = 213 control; 300 intervention), from 112
general practices (Figure 1).
Prior to recruitment, the last-recorded HbA1c was
8.3% (67 mmol/mol) for control patients on average,
compared with 8.5% (69 mmol/mol) for intervention pa-
tients (standardised difference 10.6, variance ratio 1.3) –
see Table 1. A similar proportion in each group had been
prescribed insulin in the year before recruitment (46.5%
of control patients vs. 49.7% of intervention patients).
Rates of prescription of sulphonylureas were also similar
(41.3% of control patients vs. 40.3% of intervention
patients), though a smaller proportion of control than
intervention patients had been prescribed metformin
(69.5% vs. 77.3%). Compared with the control group, the
intervention group was larger (300 vs. 213), more likely
to be female (46.7% of patients vs. 35.7%) and younger
(mean age 63.9 years vs. 66.2).
During the 12-month trial period, the majority of the
513 patients included in the study had at least one
recorded HbA1c (95.3% of control patients and 93.0% of
intervention patients). The mean number of HbA1c
readings per patient during this period was 1.9 (median
2, range 0–7), with no difference in the distribution of
number of readings between control and intervention
groups (chi-square statistic 5.14, p = 0.64). Readings ap-
peared to be recorded uniformly within the trial period
(Kolmogorov-Smirnov statistic 0.028, p > 0.25).
The repeated measures analysis (conducted on the full
sample of 513 patients) found that the intervention
patients had lower HbA1c than control patients during
the 12-month trial period, by 0.21% (2.3 mmol/mol) in
favour of the intervention group. This difference was
statistically significant at the 5% level, with a 95% confi-
dence interval ranging from 0.04% (0.4 mmol/mol) to
0.38% (4.2 mmol/mol) (p = 0.013).
Secondary analysis was restricted to the 457 patients
with at least one HbA1c reading in the years before and
after recruitment (Table 2). Among control patients,
mean HbA1c was 8.41% (68 mmol/mol) during the year
before recruitment, and 8.38% (68 mmol/mol) during
the 12-month trial period. Mean HbA1c thus showed
little change among control patients. However, it fell
among intervention patients from 8.38% (68 mmol/mol)
to 8.15% (66 mmol/mol). Differences between treatment
groups were not statistically significant in the un-
adjusted analysis, though they reached significance
when adjusting for baseline characteristics - see Table 2.
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Sensitivity analysis found that, although effect sizes did
not depend heavily on the model specification, statis-
tical significance was not always reached (Additional
file 2).
Compared with controls, a smaller proportion of the
intervention group appeared to have high mean
HbA1c during the trial period (Figure 2). During the
12-month trial period, 30.4% of control patients had
mean HbA1c less than the 7.5% threshold targeted by
general practices (58 mmol/mol), compared with 38.0% of
intervention patients. This difference was not statisti-
cally significant in the unadjusted analysis (odds ratio
1.43, 95% CI, 0.94 to 2.17, p = 0.095), though it
approached significance when adjusting for baseline
characteristics (adjusted odds ratio 1.63, 95% CI, 0.99
to 2.68, p = 0.053).
Discussion
The Whole Systems Demonstrator trial tested the effect
of telehealth in the context of whole system redesign in
three areas of England. Its pragmatic design allowed for
the recruitment of very large numbers of patients, making
it the largest randomised controlled trial of telehealth
conducted thus far. We found that, among a subset of 513
participants with type 2 diabetes, telehealth was associated
with modestly lower HbA1c than usual care over a 12-
month period, by around 0.21% (2.3 mmol/mol). Follow-
ing recruitment, HbA1c fell from 8.38% to 8.15% (68 to
66 mmol/mol) among telehealth participants, whilst there
was broadly no change among controls. Telehealth ap-
peared to be associated with a higher proportion of pa-
tients meeting the 7.5% (58 mmol/mol) threshold that was
targeted by general practices in England at the time of the
Figure 1 Flow of patients into the study.
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Cornwall 20.2 22.3 5.2
Kent 24.9 14.3 −26.8
Newham 54.9 63.3 17.2
Other targeted conditions
COPD 11.3 16.3 14.7
Heart failure 12.7 13.0 1.0
Age
Mean (SD) age in years 66.2 (11.9) 63.9 (13.0) −18.2 (1.2)
<65 years 43.7 50.7 14.1
65-74 years 31.0 29.7 −2.9
75-84 years 21.1 16.3 −12.3
> = 85 years 4.2 3.3 −4.7
Female 35.7 46.7 22.5
Ethnicity
White 55.4 51.7 −7.5
Other 33.3 30.3 −6.4
Unknown 11.3 18.0 19.1
Area-level deprivation score*
Mean (SD) 34.2 (13.0) 36.7 (14.4) 18.3 (1.2)
First quartile 4.2 4.3 0.5
Second quartile 8.0 7.0 −3.7
Third quartile 23.9 18.7 −12.9
Fourth quartile 63.8 70.0 13.1
Mean Combined Model score (SD)** 0.25 (0.18) 0.24 (0.19) −3.8 (1.2)
Ischemic heart disease 14.6 8.3 −19.6
Diabetes management in prior year
Insulin 46.5 49.7 6.4
Sulphonylureas 41.3 40.3 −2.0
Metformin 69.5 77.3 17.8
Thiazolidinediones 9.4 12.3 9.5
Smoking status
Never 42.3 46.3 8.2
Current 12.2 10.7 −4.8
Ex smoker 45.5 43.0 −5.1
Latest clinical readings (mean (SD))
HbA1c 8.3 (1.7) 8.5 (1.8) 10.6 (1.3)
Body-mass index (BMI)*** 30.3 (5.9) 31.8 (6.6) 24.2 (1.3)
Cholesterol**** 4.3 (1.1) 4.3 (1.4) 2.5 (1.5)
Systolic blood pressure 134.4 (17.6) 132.1 (19.1) −12.6 (1.2)
Diastolic blood pressure 74.3 (10.2) 75.0 (10.3) 6.3 (1.0)
Latest HbA1c < = 7.5% 35.7 33.3 −4.9
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trial, though this did not quite reach statistical significance
(38.0% vs. 30.4% of patients, adjusted odds ratio 1.63, 95%
CI, 0.99 to 2.68, p = 0.053).
Strengths and weaknesses
The complexity of the recruitment processes and the
size of the trial meant that we relied on routine electronic
data for HbA1c, rather than bespoke data collection.
Routine data offer promising opportunities for research
[34], and this study offers one model for how routinely-
recorded clinical information can be used in analyses of
randomised controlled trials. One challenge was that
the timing of the available HbA1c measurements was
contingent on decisions made by patients and profes-
sionals, rather than, as in a conventional trial, specified
by the trial protocol. If, for example, HbA1c tends to be
taken in response to concerns about patient health, we
may have disproportionately sampled HbA1c when it
was higher. In assessing the potential bias from our
data-collection approach, we were reassured that the
intervention itself did not appear to lead to changes in
the frequency of measurement. Further, results from
our primary and secondary analyses were similar. As
the secondary analysis averaged multiple readings re-
corded for each individual, they ensured that all individ-
uals contributed equal weight to the analysis, regardless
of the number of readings made for each one The
similarity of the results of the analyses suggests that
they were not biased towards patients who attended
general practice most often. We note that our findings
reflect the average HbA1c recorded over a 12-month
period. We did not assess whether short-term effects on
HbA1c (such as at three months) were larger than those
at 12 months. This could have occurred, if, for example,
patients adhered to the monitoring schedule more
closely at the start than at the end of the trial.
Selection bias is recognised as a risk in cluster rando-
mised trials, particularly when the individuals recruiting
patients have foreknowledge about treatment allocations,
as might sometimes have been the case in this trial. Re-
assuringly, we did not find large baseline differences
between intervention and control groups in the pri-
mary study of all 3,230 patients [19]. In the current
study, with smaller samples, larger differences were
more likely to have occurred by chance. The most not-
able difference concerned the size of the treatment
groups (300 patients for the intervention group vs. 213
patients for the control group). Furthermore, although
general practices in the intervention and control arms
typically provided similar numbers of patients for the
current study (median 3 patients in each arm), some
intervention practices supplied up to 38 patients, com-
pared with up to 16 for control practices. This pattern
was also not systematic across the wider trial, and
Table 1 Baseline characteristics of study cohort (all data are proportions of patients unless otherwise specified)
(Continued)
Mean (SD) health care contacts per patient in prior year
Practice nurses 6.0 (7.5) 4.9 (7.7) −15.0 (1.1)
General practitioner 8.5 (7.2) 9.2 (6.0) 10.2 (0.7)
Elective admissions 0.5 (1.2) 0.4 (0.8) −15.7 (0.5)
Emergency admissions 0.5 (1.1) 0.5 (1.0) −3.7 (0.7)
Outpatient attendances 6.7 (8.9) 5.8 (6.9) −11.1 (0.6)
Emergency department visits 0.5 (1.1) 0.7 (1.3) 16.2 (1.2)
Hospital bed days 3.3 (6.4) 3.7 (9.3) 5.4 (2.1)
SD = standard deviation.
*Based on the Index of Multiple Deprivation, 2007, attributed to small areas of residence.
**Combined Model score is the estimated probability of emergency hospitalization within the 12-month trial period [33].
***N = 189 (control); 245 (intervention).
****N = 212 (control); 298 (intervention).
Table 2 Secondary analysis of HbA1c (%) for patients with levels recorded within the year before the trial and within
the year of the trial itself
Control group mean
(standard deviation) (n = 191)
Intervention group mean
(standard deviation) (n = 266)
Difference in mean HbA1c during trial
(95% confidence interval)
Before trial During trial Before trial During trial Unadjusted Adjusted*
Mean HbA1c 8.41 (1.64) 8.38 (1.60) 8.38 (1.68) 8.15 (1.49)
−0.26 −0.30
(−0.60, 0.07) (−0.52, −0.07)
p = 0.125 p = 0.009
*Adjusted for age; sex; last recorded HbA1c, blood pressure, cholesterol quartile and BMI quartile; site (Cornwall, Kent or Newham); smoking status; co-morbid
ischemic heart disease; and diabetes management (insulin or non-insulin).
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indeed the primary study found differences in cluster
sizes in the opposite direction [19].
To limit the impact of selection bias, we conducted
analysis on an intention-to-treat basis and adjusted for
important prognostic variables including age, smoking
status, co-morbid ischemic heart disease, and diabetes
management. Adjustment tended to make estimated
effect sizes larger. The use of routine data meant that
some covariates of interest were not available, in particu-
lar time since diagnosis, prior self-monitoring activity
and micro-vascular complications. We therefore had to
rely on randomisation to balance these characteristics
between intervention and control groups. Although clus-
ter randomisation has limitations, it reduced the scope
for contamination between treatment groups as no gen-
eral practice provided care for both telehealth and con-
trol participants. Individual randomisation would not
have been acceptable to the stakeholders involved in this
study [14].
Approximately 80% of the individuals invited to par-
ticipate in the WSD trial refused to do so [19]. Such high
rates of patient refusal are not unusual for telehealth
trials [35], and by themselves suggest that telehealth
might not always meet the perceived needs of patients
and that many patients may be reluctant to change from
their current mode of care [23,36]. A qualitative study
explored the reasons given by patients for not participat-
ing in the WSD trial. These related to the requirements
for technical competence and operation of the telehealth
equipment; threats to identity, independence and self-
care; and expectations and experiences of disruption to
services [23]. One implication of the high refusal rate is
that the included patients were probably not fully repre-
sentative of the wider population with type 2 diabetes.
Compared to cross-sectional studies of the diabetes
population, the current study included a relatively high
proportion of insulin-treated patients (49.7%) [3]. Also,
baseline levels of HbA1c were higher in the current
study than in IDEATel [11] (mean 8.5% vs. 7.4%, or 69
vs. 57 mmol/mol). Some comorbidity arose from the
other two conditions targeted by WSD, namely heart
failure (affecting 13.0% of intervention patients) and
chronic obstructive pulmonary disease (affecting 16.3%).
Overall, it seems likely that we studied a population with
Figure 2 Distribution of mean HbA1c during trial period. Bands are based on Currie et al. (2010) [32].
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relatively less well-controlled diabetes. A formal, empir-
ical assessment of the generalisability of the WSD trial is
planned in relation to its primary endpoint of hospital-
isation. This assessment will use observational data sets
to compare the baseline characteristics and outcomes of
WSD control patients with the baseline characteristics
and outcomes of patients receiving usual care outside of
the trial [37].
Usual care already consisted of a blend of different
(non-telehealth) approaches to improving glycaemic
control. Information was not available on rates of self-
monitoring in the control group, but it would not have
been universal [4]. Telehealth was implemented in the
context of wider, whole-systems redesigns on-going in
the sites. This redesign might have affected care deliv-
ered to both intervention and control patients, though
a companion study found that the extent of integra-
tion achieved during the evaluation period was quite
limited [22].
Although the WSD sites were diverse, they were
selected based on their history of innovations in these
areas of care. Furthermore, there was dedicated funding
and project management for telehealth in this trial. Tele-
health might have different effects in other settings, and
important factors might include: which patients are re-
cruited; the available staff and how they undertake their
roles; other on-going approaches to managing long-term
conditions; the local context, including financial incen-
tives; integration between care teams; and the details of
the telehealth and health information technology and
monitoring systems. In general, the recruitment and mon-
itoring protocols used in randomised controlled trials can
affect outcomes for both intervention and control groups,
for example through Hawthorne effects [38].
Comparison with existing studies
Our findings are in line with previous meta-analyses of
the effect of telehealth versus usual care. One of these
meta-analyses examined 12 randomised controlled
trials and found reductions in HbA1c of around 0.22%,
or 2.4 mmol/mol (95% CI, 0.08 to 0.35%, or 0.9 to
3.8 mmol/mol) [10]. Another examined 15 trials and
found smaller impacts (−0.10% or 1.1 mmol/mol) that
did not reach statistical significance [39]. In compari-
son to these meta-analyses, larger effect sizes where
found in a review of telehealth interventions using mobile
phones for patients [40]. These interventions were associ-
ated with reductions in HbA1c of 0.8%, or 8.7 mmol/mol
(95% CI, 0.5 to 1.1%, or 5.5 to 12.0 mmol/mol). Overall,
the evidence suggests that interventions such as telehealth
are, at best, associated with modest reductions in HbA1c
compared with usual care [41].
A number of differences exist between WSD and the
previous IDEATel trial, which found larger impacts on
HbA1c [12]. For example, the telehealth services devel-
oped by the WSD sites were largely based in primary
care [14], while IDEATel contained an element of case
management under diabetologist supervision. A particu-
lar feature of WSD is that we left the development of
telehealth services largely to the participating sites. Al-
though the resulting plurality might be problematic for
the purposes of replicating the specific interventions, in
some ways it is the merit of a pragmatic trial as it means
that our results reflect decisions made by local teams,
thus increasing their generalisability to routine clinical
practice.
Conclusions
In this study, telehealth led to modest improvements in
glycaemic control among people with type 2 diabetes as
indicated by glycosylated haemoglobin (HbA1c), at least
over 12 months. The improvements (0.21%, 95% CI, 0.04%
to 0.38% - equating to 2.3 mmol/mol, 95% CI, 0.4 to 4.2)
are consistent with previous meta-analyses.
Although further investigation is warranted, it seems
doubtful that the improvements in HbA1c that we
detected in the current study were sufficiently large to
produce substantial patient benefit. Other interventions,
which report reductions in complications from diabetes,
have shown larger reductions in HbA1c than the current
study. For example, the Diabetes Control and Complica-
tions Trial (DCCT) reported that intensive therapy
produced HbA1c values that were around 2% lower than
standard therapy, among insulin-dependent patients
[42]. Also, on the basis of the current study, it is not
possible to know whether reductions in HbA1c would
be sustained beyond one year. The United Kingdom Pro-
spective Diabetes Study (UK PDS) found that intensive
glycaemic control was associated with continuing reduc-
tions in the risk of complications, even though HbA1c
converged to the level experienced by those receiving
conventional therapy after the first year [43]. However,
the short-term HbA1c differences detected by the UK
PDS were larger than those in the current study, and
were assessed at 12 months, rather than across a
12-month period as in the current study.
A final and important consideration is that, since the
DCCT, research has suggested that the implications of
tighter glycaemic control on patient outcomes are un-
clear, and furthermore depend on the patient [2,32,44].
Thus, although some meta-analyses have found that in-
tensive glycaemic control is associated with lower rates
of major cardiovascular events in trials [45-47], another
has suggested that the harms associated with severe
hypoglycaemia might counterbalance the potential bene-
fits of intensive glycaemic control [48]. An observational
study found a U-shaped relationship between HbA1c
and survival, with more deaths occurring at the bottom
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as well as the top of the HbA1c distribution compared
with at the middle (7.5% or 58.5 mmol/mol). Another
observational study found a U-shaped relationship be-
tween HbA1c and self-reported hypoglycaemia [49].
In light of the complex relationship between achieved
HbA1c levels and patient outcomes, decision-making
should take account of other outputs from the Whole
Systems Demonstrator evaluation, including the forth-
coming analysis of disease-specific quality of life, and the
existing outputs regarding poor overall cost effectiveness
[21]. Future, longer-term studies could examine impacts
of telehealth on complications of diabetes, such as retin-
opathy and acute myocardial infarction.
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